Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RAPS 2004 Annual Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

CDRH staff changes: Donna-Bea Tillman, PhD, is named Office of Device Evaluation director on a permanent basis. She had been serving as the acting director since former director Dan Schultz, MD, ascended to the CDRH helm earlier this year (1"The Gray Sheet" July 26, 2004, p. 3). Lily Ng is appointed director of executive programs; she had held the position on an acting basis for the last three months. Ng brings experience with reuse policy to her role within the Office of the Center Director. Also joining OCD on a formal basis is Joanne Less, PhD, who will assume the role of associate director for clinical research & government affairs. Less will continue to lead MDUFMA implementation, but also will intensify her involvement in coordinating intra- and intercenter human subjects' protection policies...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel